The Cardio-Metabolic Clinic

Inclusion 21

• Minimum age: 19 years
• Study condition: Diabetes Mellitus, Type 2, Cardiovascular Diseases
• Inclusion:
• \>18 years
• Capable of giving written informed consent
• Established diagnosis of T2D
• Having established heart or vascular disease defined as either:
• Atherosclerotic disease defined as:
• Prior acute coronary syndrome (ACS).
• Chronic coronary syndrome defined as the combination of: Angina pectoris AND coronary atherosclerosis assessed with either Coronary CT angiography (CTA) or Myocardial-scintigraphy (MPI) or Coronary angiography (CAG) AND treatment with statins and/or acetylsalicylic acid.
• Stroke.
• Peripheral arterial disease (PAD) defined as: Claudication intermittence in combination with pathological ABI AND/OR vascular PAD surgery AND/OR ischemic amputation.
• Ischemic heart disease defined by one of the following criteria: a) Myocardial-scintigraphy: \>10% reversibility OR b) Coronary CT angiography: Coronary Artery Calcium (CAC)-score \>100.
• Heart failure (HF): HF with reduced ejection fraction (HFrEF), HF with Mildly reduced ejection fraction (HFmrEF), HF with preserved ejection fraction (HFpEF)
• Atrial fibrillation and/or flutter, including paroxysmal, persistent and chronic disease
• Valvular heart disease (which requires control in outpatient clinic of cardiology), such as aortic valve stenosis, mitral valve insufficiency, and patients with aortic dilatation
• Hypertension treated with at least three antihypertensive drugs
• Exclusion:
• Life expectancy less than 5 years for any reason
• Type 1 Diabetes Mellitus
• Participation in another clinical trial with an investigational product or device that could interfere with the primary and/or secondary endpoints of this study